spacer
home > ebr > winter 2002 > novel antibiotics to counteract the global threat of superbugs
PUBLICATIONS
European Biopharmaceutical Review

Novel Antibiotics to Counteract the Global Threat of Superbugs

The introduction of antibiotics in the 1950s and 1960s revolutionised medicine, to such an extent that in 1969 the US Surgeon General famously declared: "The time has come to close the book on infectious disease". Following this initial optimism, many companies left the field. While industry dollars were spent elsewhere, bacteria became resistant to antibiotics at a rapid pace. Despite renewed efforts in antibiotic discovery, resistance is now a global threat to public health.Changing population demographics, increasing use of invasive procedures, the spread of HIV, an increasing number of immunocompromised patients and misuse of broad spectrum antibiotics have meant that new pathogens have emerged, some of which are resistant to one or several of the antibiotics normally used to treat them (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne Gill, Head of Microbiology at PanTherix Ltd Anne Gill obtained her PhD in Medical Microbiology from the University of Edinburgh, specialising in the mechanisms of antibiotic action and resistance. After conducting post-doctoral research, Anne joined PanTherix, where she now holds the post of Head of Microbiology.
PanTherix is an anti-infectives company using structure-guided drug design to discover and develop antibiotics acting on novel targets.

spacer
Anne Gill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement